{Reference Type}: Journal Article
{Title}: Eosinophilic esophagitis in the era of biologics.
{Author}: Rossi CM;Santacroce G;Lenti MV;di Sabatino A;
{Journal}: Expert Rev Gastroenterol Hepatol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 1
{Factor}: 4.095
{DOI}: 10.1080/17474124.2024.2374471
{Abstract}: <B>UNASSIGNED: </B>Eosinophilic esophagitis (EoE) is a chronic inflammatory, disabling disorder characterized by prominent eosinophilic inflammation of the esophagus, leading to troublesome symptoms including dysphagia and food impaction. The natural history of EoE is poorly known, but it may lead to esophageal strictures. The therapeutic armamentarium is expected to grow in the near future, especially due to the availability of novel biological therapies targeting crucial inflammatory pathways of EoE.<BR><B>UNASSIGNED: </B>In this review, we discuss the main clinical features and natural history of EoE, focusing on the current therapeutic strategies, as well as past and current trials investigating biologics for its treatment.<BR><B>UNASSIGNED: </B>Dupilumab has been the first approved biologic drug for the treatment of EoE; long-term studies assessing how it could change the natural history of EoE are awaited. Novel biological drugs or other molecules are currently under study and could change the current treatment algorithms in the near future. Proper drug positioning and long term 'exit strategies' are yet to be defined.